safusidenib
Small molecule
Evidence outlook · registrational
Glioma: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2028-12-01.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
SIGMA NCT05303519 · Glioma Registry: NCT05303519 | 3 | Part 1: Incidence of adverse events (AEs) and serious adverse events (SAEs) (From participants sign ICF to 30 days after last dose,average 2 years); Part 2: Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) per Response Assessment in Neuro-Oncology (RANO) 2.0 (From randomization until the date of first documented disease progression, average 2 years); Part 3 Objective Response Rate (ORR) (Complete Response (CR), Partial Response (PR) and Minor Response (MR)) assessed by Blinded Independent Central Review (BICR) per Response Assessment in Neuro-Oncology (RANO) 2.0 (From the first dose of study drug until the date of first documented disease progression, average 18 months) 2028-12-01 | In progress: results expected 1 Dec 2028 | not yet graded | link ↗ |
View 1 more trial
NCT07712757 NCT07712757 · Glioma Registry: NCT07712757 | 3 | Progression Free Survival (PFS) assessed by Blinded Independent Central Review (BICR) per modified Response Assessment in Neuro-Oncology (RANO) 2.0 (From the date of randomization until the date of first documented disease progression, approximately 30 months) 2029-05 | In progress: results expected 1 May 2029 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
Other Mutant IDH1 drugs
2 other tracked programmes target this mechanism, 2 of them ahead of this one.
This drug's own stage for Glioma: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Safusidenib: this drug | Phase 3 | Small molecule | Mutant IDH1 | not yet graded | No reviewed efficacy summary in this indication | |
| Dabrafenib | Approved | Small molecule | BRAF V600E/V600K/V600D (also wild-type BRAF/CRAF) | not yet graded | No reviewed efficacy summary in this indication | |
| Dordaviprone | Approved | Small molecule | Mitochondrial caseinolytic protease P (ClpP), Dopamine D2 receptor | Weak signal | No reviewed efficacy summary in this indication | |
| Ivosidenib (Tibsovo) | Approved(overall) | Small molecule | Mutant IDH1 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Temozolomide | Approved | Small molecule | DNA alkylation (O6-guanine) | Partial signal | NCT00626990: Overall survival: adjuvant temozolomide vs none, median 82.3 vs 46.9 months, hazard ratio 0.64 (95% CI 0.52 to 0.79), p<0.0001; concurrent temozolomide vs none, 66.9 vs 60.4 months, hazard ratio 0.97 (95% CI 0.73 to 1.28), p=0.76 (CT.gov posted results). | |
| Tovorafenib | Approved | Small molecule | Kinase Inhibitor | Weak signal | No reviewed efficacy summary in this indication | |
| Trametinib | Approved | Small molecule | MEK1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| Luvometinib | Phase 3 | Small molecule | MEK1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| Abemaciclib (Verzenio) | Phase 2 | Small molecule | CDK4 and CDK6 | not yet graded | No reviewed efficacy summary in this indication | |
| Olutasidenib | Phase 2 | Small molecule | Mutant IDH1 | not yet graded | No reviewed efficacy summary in this indication | |
| Crelosidenib | Phase 1 | Small molecule | Mutant IDH1 and IDH2 | not yet graded | No reviewed efficacy summary in this indication | |
| Vebreltinib | Phase 1 | Small molecule | MET | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow safusidenib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.